Merck & Co, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Merck & Co. reported a net loss for Q1 2026, impacted by significant acquisition charges, though operational sales showed a 5% increase driven by oncology and animal health segments.
NYSE
Merck reported a significant increase in net income and EPS for Q3 2025, driven by strong performance in its oncology and cardiovascular franchises, despite declines in vaccines and virology.
NYSE
Merck reports a significant drop in second-quarter net income and sales, driven by vaccine declines and increased restructuring costs, despite strong oncology growth and new product launches.
NYSE
10-Q: Merck & Co. Reports Q1 2025 Results: Keytruda Growth Offsets Vaccine Decline, Januvia Sales Surge
Merck & Co.'s Q1 2025 results show a slight sales decrease due to vaccine and virology declines, balanced by oncology and diabetes growth, with Keytruda remaining a key driver.
NYSE
Merck & Co. announced its third-quarter 2024 results, marked by revenue growth driven by oncology and animal health, alongside significant acquisition charges and restructuring costs.
NYSE
Merck & Co. reported a 7% increase in worldwide sales for the second quarter of 2024, driven by strong performance in its oncology and vaccine franchises.
NYSE
Merck & Co. reported a strong first quarter in 2024, with a 9% increase in sales driven by oncology and vaccine performance, despite some headwinds in other areas.